Stock Events

Stock Events

Corgi IP Licensing & Royalties 

$26.83
142
+$0.56+2.13% Friday 19:22

Statistics

Day High
26.84
Day Low
26.84
52W High
26.92
52W Low
4.75
Volume
100
Avg. Volume
-
Mkt Cap
47.54M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2SepExpected
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Q4 2025
Q1 2026
Next
-2.86
-0.49
1.89
4.26
Expected EPS
-1.2
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-34.61MNet Income

Analyst Ratings

60Average Price Target
The highest estimate is 60.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PTNT. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap183.12B
Amgen develops therapeutics in areas similar to Palatin, including reproductive health and cardiovascular diseases, making them direct competitors in the biopharmaceutical market.
Pfizer
PFE
Mkt Cap147.62B
Pfizer competes with Palatin in the development of novel drugs, including treatments in sexual health, where Palatin has a significant focus.
Lilly(Eli) &
LLY
Mkt Cap949.7B
Eli Lilly offers products in men's health and other areas that overlap with Palatin's focus, particularly in treatments for conditions like erectile dysfunction.
Abbvie
ABBV
Mkt Cap381.1B
AbbVie, with its broad range of pharmaceutical products, competes in the same therapeutic areas as Palatin, including women's health and hormonal therapies.
Merck
MRK
Mkt Cap302.33B
Merck operates in various healthcare segments that compete with Palatin, including the development of drugs for sexual health and cardiovascular diseases.
Novartis
NVS
Mkt Cap290.05B
Novartis competes with Palatin in multiple areas, including cardiovascular and metabolic conditions, through its extensive research and development in these fields.
Bristol-Myers Squibb
BMY
Mkt Cap121.42B
Bristol Myers Squibb's diverse range of pharmaceutical products in areas like cardiovascular diseases places it in competition with Palatin Technologies.
GSK
GSK
Mkt Cap103.1B
GlaxoSmithKline has a presence in the sexual health market, making it a competitor to Palatin, especially in the development of treatments for related conditions.
Astrazeneca
AZN
Mkt Cap290.06B
AstraZeneca's work in cardiovascular and metabolic diseases competes with Palatin's research and development efforts in similar therapeutic areas.

About

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Show more...
CEO
Dr. Carl Spana Ph.D.
Employees
29
Country
United States
ISIN
US2189466483

Listings

BATS
US
PTNT
STU
DE
PTN.STU
LSE
GB
0KF3.LSE
XASE
US
PTN

0 Comments

Share your thoughts

FAQ

What is Corgi IP Licensing & Royalties stock price today?▼
The current price of PTNT is $26.83 USD — it has increased by +2.13% in the past 24 hours. Watch Corgi IP Licensing & Royalties stock price performance more closely on the chart.
What is Corgi IP Licensing & Royalties stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Corgi IP Licensing & Royalties stocks are traded under the ticker PTNT.
Is Corgi IP Licensing & Royalties stock price growing?▼
PTNT stock has risen by +6.05% compared to the previous week, the month change is a +17.57% rise, over the last year Corgi IP Licensing & Royalties has showed a +370.7% increase.
What is Corgi IP Licensing & Royalties market cap?▼
Today Corgi IP Licensing & Royalties has the market capitalization of 47.54M
When is the next Corgi IP Licensing & Royalties earnings date?▼
Corgi IP Licensing & Royalties is going to release the next earnings report on September 02, 2026.
What were Corgi IP Licensing & Royalties earnings last quarter?▼
PTNT earnings for the last quarter are -0.37 USD per share, whereas the estimation was -1.24 USD resulting in a +70.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Corgi IP Licensing & Royalties revenue for the last year?▼
Corgi IP Licensing & Royalties revenue for the last year amounts to 0 USD.
What is Corgi IP Licensing & Royalties net income for the last year?▼
PTNT net income for the last year is -34.61M USD.
How many employees does Corgi IP Licensing & Royalties have?▼
As of May 26, 2026, the company has 29 employees.
In which sector is Corgi IP Licensing & Royalties located?▼
Corgi IP Licensing & Royalties operates in the Manufacturing sector.
When did Corgi IP Licensing & Royalties complete a stock split?▼
The last stock split for Corgi IP Licensing & Royalties was on August 12, 2025 with a ratio of 1:50.
Where is Corgi IP Licensing & Royalties headquartered?▼
Corgi IP Licensing & Royalties is headquartered in Monmouth Junction, United States.